These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38626366)

  • 41. Venetoclax alone or in combination with other regimens treatment achieve deep and sustained remission of relapsed/refractory chronic lymphocytic leukemia: a meta-analysis.
    Tang X; Zou W; Peng P; Bai Y
    Clin Exp Med; 2022 May; 22(2):161-171. PubMed ID: 34224006
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An update of venetoclax and obinutuzumab in chronic lymphocytic leukemia.
    Salvaris R; Opat S
    Future Oncol; 2021 Feb; 17(4):371-387. PubMed ID: 33064021
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
    Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
    Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
    [TBL] [Abstract][Full Text] [Related]  

  • 44. BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL.
    Mhibik M; Gaglione EM; Eik D; Kendall EK; Blackburn A; Keyvanfar K; Baptista MJ; Ahn IE; Sun C; Qi J; Rader C; Wiestner A
    Blood; 2021 Nov; 138(19):1843-1854. PubMed ID: 34046681
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia.
    Bennett R; Anderson MA; Seymour JF
    J Hematol Oncol; 2023 Jul; 16(1):72. PubMed ID: 37422670
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia.
    Rogers KA; Huang Y; Ruppert AS; Awan FT; Heerema NA; Hoffman C; Lozanski G; Maddocks KJ; Moran ME; Reid MA; Lucas M; Woyach JA; Whitlow WT; Jones JA; Byrd JC
    Blood; 2018 Oct; 132(15):1568-1572. PubMed ID: 30111609
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.
    Mato AR; Hill BT; Lamanna N; Barr PM; Ujjani CS; Brander DM; Howlett C; Skarbnik AP; Cheson BD; Zent CS; Pu JJ; Kiselev P; Foon K; Lenhart J; Henick Bachow S; Winter AM; Cruz AL; Claxton DF; Goy A; Daniel C; Isaac K; Kennard KH; Timlin C; Fanning M; Gashonia L; Yacur M; Svoboda J; Schuster SJ; Nabhan C
    Ann Oncol; 2017 May; 28(5):1050-1056. PubMed ID: 28453705
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Low incidence of tumor lysis syndrome in elderly patients with chronic lymphocytic leukemia treated with venetoclax under real-world conditions: results from the prospective observational VeRVe study.
    Schwaner I; Kuhn T; Losem C; Wolff T; Otremba B; Zaiss M; Hülsenbeck J; Famulla K; Nösslinger T; Rossi D
    Ann Hematol; 2024 Jun; 103(6):2013-2020. PubMed ID: 38421404
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Current diagnosis and treatment of chronic lymphocytic leukaemia].
    Cramer P; von Tresckow J; Eichhorst B; Hallek M
    Dtsch Med Wochenschr; 2020 Aug; 145(16):1139-1144. PubMed ID: 32791549
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
    Del Poeta G; Postorino M; Pupo L; Del Principe MI; Dal Bo M; Bittolo T; Buccisano F; Mariotti B; Iannella E; Maurillo L; Venditti A; Gattei V; de Fabritiis P; Cantonetti M; Amadori S
    Drugs Today (Barc); 2016 Apr; 52(4):249-60. PubMed ID: 27252989
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Lei MM; Sorial MN; Lou U; Yu M; Medrano A; Ford J; Nemec RA; Abramson JS; Soumerai JD
    Leuk Lymphoma; 2024 May; 65(5):653-659. PubMed ID: 38293753
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.
    Wierda WG; Allan JN; Siddiqi T; Kipps TJ; Opat S; Tedeschi A; Badoux XC; Kuss BJ; Jackson S; Moreno C; Jacobs R; Pagel JM; Flinn I; Pak Y; Zhou C; Szafer-Glusman E; Ninomoto J; Dean JP; James DF; Ghia P; Tam CS
    J Clin Oncol; 2021 Dec; 39(34):3853-3865. PubMed ID: 34618601
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study.
    Hillmen P; Rawstron AC; Brock K; Muñoz-Vicente S; Yates FJ; Bishop R; Boucher R; MacDonald D; Fegan C; McCaig A; Schuh A; Pettitt A; Gribben JG; Patten PEM; Devereux S; Bloor A; Fox CP; Forconi F; Munir T
    J Clin Oncol; 2019 Oct; 37(30):2722-2729. PubMed ID: 31295041
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Frontline Therapy of CLL-Changing Treatment Paradigms.
    Coombs CC
    Curr Hematol Malig Rep; 2024 Apr; 19(2):65-74. PubMed ID: 38337108
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Metabolic and toxicological considerations of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Wolska-Washer A; Robak P; Witkowska M; Robak T
    Expert Opin Drug Metab Toxicol; 2024 Apr; 20(4):207-224. PubMed ID: 38516702
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication.
    Lu P; Wang S; Franzen CA; Venkataraman G; McClure R; Li L; Wu W; Niu N; Sukhanova M; Pei J; Baldwin DA; Nejati R; Wasik MA; Khan N; Tu Y; Gao J; Chen Y; Ma S; Larson RA; Wang YL
    Blood Cancer J; 2021 Feb; 11(2):39. PubMed ID: 33602908
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment patterns in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma post covalent Bruton tyrosine kinase inhibitor treatment: a Japanese claims database study.
    Maruyama D; Wang C; Tanizawa Y; Cai Z; Huang Y; Tajimi M; Kusumoto S
    J Clin Exp Hematop; 2023; 63(4):219-229. PubMed ID: 38148012
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bruton Tyrosine Kinase Inhibitors: Present and Future.
    Burger JA
    Cancer J; 2019; 25(6):386-393. PubMed ID: 31764119
    [TBL] [Abstract][Full Text] [Related]  

  • 59. How I manage CLL with venetoclax-based treatments.
    Wierda WG; Tambaro FP
    Blood; 2020 Apr; 135(17):1421-1427. PubMed ID: 32076705
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia.
    Fischer K; Al-Sawaf O; Hallek M
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):357-362. PubMed ID: 33275717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.